UK approval for Gilead HIV drug with blockbuster potential

The UK’s Medicines and Healthcare Regulatory Agency (MHRA) has approved Sunlenca (lenacapavir) injection and tablets, in combination with other antiretrovirals, in adults with multi-drug resistant HIV infection for whom it is otherwise not possible to construct a suppressive anti-viral regimen.

Gilead Sciences’ (Nasdaq: GILD) therapy is a first-in-class capsid inhibitor with a multi-stage mechanism of action that has no known cross resistance to other existing drug classes, offering a new, every six-month treatment option for eligible adults with HIV whose virus no longer effectively responds to their current therapy.

"Lenacapavir will now be the first twice-yearly treatment for people who struggle with multi-drug resistant HIV"